Schulenburg Axel, Rüsing Lina Z, Bumberger Armin, Mitterbauer Margit, Rabitsch Werner
Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Department of Medicine I, Stem Cell Transplantation Unit, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Wien Klin Wochenschr. 2024 Oct 4. doi: 10.1007/s00508-024-02451-0.
Chimeric antigen receptor (CAR)-T cell therapy is a new and successful treatment for otherwise refractory malignancies but despite the growing number of applications, this form of treatment is still associated with significant toxicity. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in particular are common and dangerous side effects. This report is about two patients who received CAR‑T cell therapy and subsequently developed ICANS. This was successfully treated. During CAR‑T cell therapy, a blood marker, S100, was monitored daily. It correlated with the occurrence and progression of ICANS.
嵌合抗原受体（CAR）-T细胞疗法是一种针对难治性恶性肿瘤的新型成功治疗方法，但尽管应用数量不断增加，这种治疗形式仍伴有显著毒性。细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）尤其是常见且危险的副作用。本报告讲述了两名接受CAR-T细胞疗法并随后发生ICANS的患者。该病症得到了成功治疗。在CAR-T细胞治疗期间，每日监测血液标志物S100。它与ICANS的发生和进展相关。
